论文部分内容阅读
目的:分析老年重症心力衰竭急诊内科采用美托洛尔和厄贝沙坦氢氯噻嗪治疗的临床疗效。方法:选取本院自2010年8月至2014年8月收治的50例老年重症心力衰竭患者作为本次研究的观察对象,按照随机双盲发将其随机分为两组,即观察组和对照组,各25例,对照组采用常规的治疗心衰的方法进行治疗,观察组则在常规治疗的基础上给予患者美托洛尔和厄贝沙坦氢氯噻嗪进行治疗,对两组患者进行为期1年的随访,比较两组患者临床治疗效果、左心室射血分数(LVEF)以及B型脑钠肽(BNP)的改善情况,以及不良反应、复发率以及死亡率等情况。结果:研究结果显示,观察组临床总有效率明显较对照组高,LVEF以及BNP的改善情况也较对照组好,不良反应的发生率以及复发率、死亡率均低于对照组,差异具有统计学意义(P<0.05)。结论:对老年重症心力衰竭急诊内科的患者在进行常规的心衰治疗的基础上给予其美托洛尔和厄贝沙坦氢氯噻嗪,能够有效的改善其心功能,并且疗效显著,安全性能较高,能有效降低患者心衰的复发率以及死亡率。
OBJECTIVE: To analyze the clinical effects of metoprolol and irbesartan hydrochloride in the treatment of elderly patients with severe heart failure. Methods: Fifty elderly patients with severe heart failure who were treated in our hospital from August 2010 to August 2014 were selected as observation subjects. They were randomly divided into two groups according to randomized double blind-blind treatment: observation group and control group Group, 25 cases in each group. The control group was treated with the conventional method of treating heart failure. The observation group was given metoprolol and irbesartan hydrochloride hydrochlorothiazide for treatment on the basis of routine treatment. The patients in the two groups were treated with 1 Year follow-up. The clinical outcomes, LVEF and BNP were compared between the two groups. The adverse reactions, relapse rates and mortality rates were also compared. Results: The results showed that the total effective rate in the observation group was significantly higher than that in the control group. The improvement in LVEF and BNP was also better than that in the control group. The incidence of adverse reactions, relapse rate and mortality were lower than those in the control group Significance (P <0.05). CONCLUSIONS: Patients with senile severe heart failure in emergency medicine are given metoprolol and irbesartan hydrochlorothiazide on the basis of routine heart failure treatment, which can effectively improve their cardiac function, and have a remarkable curative effect and a high safety performance , Can effectively reduce the recurrence rate of patients with heart failure and mortality.